Vasoactive intestinal peptide in shock and heart failure.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  The Lancet

• Publication date

  1983-03-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(83)92232-8PMID 6131249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The gut hormone profile of fulminant hepatic failure.

  1981cited by this paper
• Plasma vasoactive intestinal polypeptide (VIP) levels and intestinal ischaemia

  1978cited by this paper
• Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.

  1978cited by this paper
• Mechanism of pancreatic polypeptide release in man.

  1977cited by this paper
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine

  1970cited by this paper

• VASOACTIVE INTESTINAL PEPTIDE ( VIP ) , AND THE HEMORRHAGIC SHOCK : A POSSIBLE RELATIONSHIP ?

  2007cites this paper
• Vasoactive intestinal peptide—release from the heart and response in heart failure due to left ventricular pressure overload

  2006cites this paper
• The changes in circulating levels of vasoactive intestinal polypeptide during exercise and its reproducibility for detection of myocardial ischemia.

  2005cites this paper
• Neuroendocrine changes in chronic cardiac failure

  2004cites this paper
• Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure?

  2003cites this paper
• Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure

  2003cites this paper
• Vasoactive intestinal peptide: cardiovascular effects.

  2001cites this paper
• Neuropeptide variability in man

  2000cites this paper
• Distributions of VIP, substance P, neurokinin A and neurotensin in rat heart: an immunocytochemical study.

  1999cites this paper
• Early increase of vasoactive intestinal peptide in acute myocardial infarction.

  1996cites this paper
• Effects of endopeptidase 24.11 inhibition on plasma and tissue concentrations of vasoactive intestinal peptide.

  1995cites this paper
• Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium.

  1994cites this paper
• Chapter 18 – Perivascular Peptides in the Coronary Circulation: Relation to Pathophysiology

  1993cites this paper
• Lack of circadian rhythm of plasma concentrations of vasoactive intestinal peptide in patients with orthotopic heart transplants.

  1993cites this paper
• Mast cells, vasoactive intestinal peptide (VIP), and the hemorrhagic shock: a possible relationship?

  1993cites this paper
• Regulatory peptides in the plasma of patients with chronic cardiac failure at rest and during exercise.

  1992cites this paper
• Mast cell degranulation in hemorrhagic shock in rats and the effects of vasoactive intestinal peptide, aprotinin and H1 and H2-receptor blockers on degranulation.

  1991cites this paper
• Peptides in the mammalian cardiovascular system

  1987cites this paper
• Action and localization of vasoactive intestinal peptide in the coronary circulation: evidence for nonadrenergic, noncholinergic coronary regulation.

  1986cites this paper
• Renal function during vasoactive intestinal peptide (VIP) infusions in normal man and patients with liver disease.

  1984cites this paper
• The in vitro chronotropic and inotropic effects of vasoactive intestinal peptide (VIP) on the atria and ventricular papillary muscle from Cynomolgus monkey heart.

  1984cites this paper
• VASOACTIVE INTESTINAL PEPTIDE-SECRETING TUMOR (VIPoma)

  year unknowncites this paper